GALTHealthcare · BiotechnologyGALT Stock Forecast: Galectin Therapeutics, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Galectin Therapeutics, Inc. hold a median 12-month price target of $11 — +263.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 1 Aug 2026 — in the upper half.
GALT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Galectin Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (77): Sales and profits are climbing, and climbing faster than before.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Galectin Therapeutics, Inc. — and when they’d sell — is the membership.
GALT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GALT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +263.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $11 |
| 17 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2025 | HC Wainwright & Co. | Assumes | Buy | $6.00 |
| 2 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 27 Dec 2024 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 May 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Apr 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Aug 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Apr 2020 | B. Riley FBR | Maintains | Buy | — |
| 3 Apr 2020 | B. Riley Securities | Maintains | Buy | — |
| 17 Mar 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Feb 2019 | B. Riley FBR | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GALT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Galectin Therapeutics, Inc. (GALT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −6.2×
- Price / sales
- —
- Price / book
- −1.5×
- EV / EBITDA
- −16.2×
Cheaper than 91% of US stocks
Cheaper than 94% of US stocks
Cheaper than 88% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 24.5%
- Return on assets
- −80.4%
- Dividend yield
- —
Higher than 85% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GALT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GALT appears on the weeks it earns a place.
Frequently asked questions about GALT stock
What is the GALT stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Galectin Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $11 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GALT stock a buy right now?
Of the 1 analysts covering Galectin Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Galectin Therapeutics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GALT?
As at 1 Aug 2026, Galectin Therapeutics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (77 of 100).
Will GALT stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +263.0% from the last close, and Ticker Nerd's factor model ranks Galectin Therapeutics, Inc. 51 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GALT stock forecast for 2030?
No analyst covering Galectin Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.
How has GALT stock performed over the past year?
Galectin Therapeutics, Inc. returned -17.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Galectin Therapeutics, Inc. do?
Galectin Therapeutics Inc. is a biotechnology company dedicated to developing therapies that target galectin proteins involved in the pathogenesis of various diseases.
About Galectin Therapeutics, Inc.
Galectin Therapeutics Inc. is a biotechnology company dedicated to developing therapies that target galectin proteins involved in the pathogenesis of various diseases. The company's primary focus is on producing innovative drug candidates aimed at treating liver fibrosis and cancer. By leveraging its proprietary carbohydrate technology, Galectin Therapeutics develops compounds like belapectin, currently under investigation for its potential benefits in treating non-alcoholic steatohepatitis (NASH) cirrhosis with potential implications for broader therapeutic applications. The biotech sector, known for its intense focus on cutting-edge treatments in unmet medical needs, counts companies like Galectin Therapeutics as vital players in advancing medical science and offering hope for conditions lacking effective interventions. Based in the healthcare industry, Galectin's research and development initiatives hold significant relevance as they contribute to ongoing efforts to address global health challenges. With a unique emphasis on galectin proteins, the company seeks to make impactful strides in therapeutic interventions which, if successful, could bring about significant improvements in patient care and quality of life.
CEO Mr. Joel Lewis CPA · 15 employees · United States · https://galectintherapeutics.com